ASH Letter to FDA re Considerations for the Development of CAR T Products
Jun 15
2022
American Society of Hematology. (2022).
ASH Letter to FDA re Considerations for the Development of CAR T Products.
Retrieved from https://www.hematology.org/advocacy/policy-news-statements-testimony-and-correspondence/testimony-and-correspondence/ash-letter-to-fda-re-considerations-for-the-development-of-car-t-products.
American Society of Hematology.
"ASH Letter to FDA re Considerations for the Development of CAR T Products." Hematology.org.
https://www.hematology.org/advocacy/policy-news-statements-testimony-and-correspondence/testimony-and-correspondence/ash-letter-to-fda-re-considerations-for-the-development-of-car-t-products
(label-accessed March 30, 2023).
"American Society of Hematology."
ASH Letter to FDA re Considerations for the Development of CAR T Products, 30 Mar. 2023 ,
https://www.hematology.org/advocacy/policy-news-statements-testimony-and-correspondence/testimony-and-correspondence/ash-letter-to-fda-re-considerations-for-the-development-of-car-t-products.
